Mediwelcome Healthcare Management & Technology Inc. (Stock code: 2159) has announced that on 20 January 2026, a subsidiary of the company (the Potential Purchaser) entered into a non-binding memorandum of understanding (MOU) with certain potential vendors (the Potential Vendors) to explore acquiring 100% interest in MediAI Technology Development Limited and its subsidiaries (the Target Group).

The Target Group provides artificial intelligence (AI) technology primarily to global pharmaceutical and medical device companies. Its AI-powered medical vertical model focuses on specialised disease research and doctor training, while employing Web3 core blockchain technology for data authenticity, security, and traceability.

According to the MOU, the parties will exclusively negotiate for six months regarding considerations, payment terms, and other key items. During this period, the Potential Purchaser and its advisers will conduct due diligence on the Target Group, and conclusion of the deal is subject to a formal agreement. The MOU itself is not legally binding, apart from certain provisions regarding exclusivity, diligence, termination, and confidentiality.

If materialized, the potential acquisition is expected to be classified as a notifiable transaction under Chapter 14 of the Listing Rules. As discussions remain ongoing and no binding agreement has been signed, the potential acquisition may or may not proceed. Shareholders and investors are advised to exercise caution when dealing in the securities of Mediwelcome Healthcare Management & Technology Inc.